[Prevention of pancreatic fistula after pancreatoduodenectomy].

V I Stashkiv D S Gorin Ayrat Kaldarov G V Galkin

Published in: Khirurgiia (2020)

In our series combination of somatostatin analogue and glucocorticoid didn't show efficiency in prevention of CRPF in high risk patients, although difference between subgroups wasn't statistically significant (p=0.34). In low risk group patients prophylactic use of somatostatin analogue also didn't show decline of CRPF incidence and the difference between subgroups also wasn't statistically significant (p=0.46).

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
patient reported